{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:39:09Z","timestamp":1748367549107,"version":"3.40.4"},"reference-count":8,"publisher":"S. Karger AG","issue":"3-4","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2010]]},"abstract":"<i>Background:<\/i> Based on several phase III studies, oral S-1-based chemotherapy has become the standard for treatment of advanced gastric cancer in Japan. However, these studies included patients able to maintain sufficient oral intake, and the effectiveness of chemotherapy for patients unable to eat remained unclear. <i>Methods:<\/i> We retrospectively analyzed the effect of chemotherapy on patients with advanced gastric cancer who presented with inability to eat. We defined \u2018inability to eat\u2019 as requirement for daily intravenous fluids or hyperalimentation and \u2018improvement of oral intake\u2019 as no such requirement >1 week. <i>Results:<\/i> Among the 777 patients who received first-line chemotherapy, 100 patients (12.8%) were considered unable to eat and required daily intravenous fluids or hyperalimentation. Performance status was 0\u20131 in 26 patients and \u22672 in the other 74 patients. Seventy-eight patients (78%) had peritoneal metastasis and 62 patients (62%) had ascites. First-line chemotherapy with 5-fluorouracil-based regimens was used in 46 patients, taxane-based chemotherapy in 34 patients, oral fluoropyrimidine-based therapy in 19 patients, and irinotecan-cisplatin combination treatment in 2 patients. Median survival time was 5.0 months (95% confidence interval, CI, 3.9\u20136.6). Improvement in oral intake with duration for >1 week was achieved in 40 patients (40%) with the median duration of nutritional-support-free time of 3.1 months (95% CI 2.5\u20134.6). <i>Conclusion:<\/i> Chemotherapy is moderately effective in improving oral intake in patients with advanced gastric cancer with inability to eat. Further study is required to improve its prognosis.<\/jats:p>","DOI":"10.1159\/000320759","type":"journal-article","created":{"date-parts":[[2011,3,3]],"date-time":"2011-03-03T08:36:37Z","timestamp":1299141397000},"page":"211-218","source":"Crossref","is-referenced-by-count":11,"title":["Improvement of Oral Intake following Chemotherapy in Gastric Cancer Patients with an Inability to Eat"],"prefix":"10.1159","volume":"79","author":[{"given":"Kohei","family":"Shitara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Sawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tajika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Takahari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2011,3,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2003.04.130"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS1470-2045%2809%2970259-1"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2FS1470-2045%2808%2970035-4"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa073149"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093%2Fannonc%2Fmdn717"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093%2Fjjco%2Fhym054"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007%2Fs10120-005-0351-6"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007%2Fs10120-009-0517-8"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/320759","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/320759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:54:04Z","timestamp":1745438044000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000320759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":8,"journal-issue":{"issue":"3-4","published-online":{"date-parts":[[2011,3,1]]},"published-print":{"date-parts":[[2011,3,29]]}},"URL":"https:\/\/doi.org\/10.1159\/000320759","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[2010]]}}}